Efficacy of Tolvaptan in heart failure patients with preserved Ejection fraction: multicenter, RaNdomized, open-label triAL (ETERNAL)
Phase of Trial: Phase II
Latest Information Update: 02 Jan 2019
Price : $35 *
At a glance
- Drugs Tolvaptan (Primary)
- Indications Heart failure
- Focus Biomarker; Pharmacodynamics
- Acronyms ETERNAL
- 26 Dec 2018 Status changed from active, no longer recruiting to discontinued.
- 02 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 06 Jul 2013 New trial record